|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Chiang HC, Wang CY, Lee HL and Tsou TC:
Metabolic effects of CYP2A6 and CYP2A13 on
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced gene
mutation - a mammalian cell-based mutagenesis approach. Toxicol
Appl Pharmacol. 253:145–152. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Spitz MR, Wei Q, Dong Q, Amos CI and Wu X:
Genetic susceptibility to lung cancer: the role of DNA damage and
repair. Cancer Epidemiol Biomarkers Prev. 12:689–698.
2003.PubMed/NCBI
|
|
4
|
Wang LE, Cheng L, Spitz MR and Wei Q: Fas
A670G polymorphism, apoptotic capacity in lymphocyte cultures, and
risk of lung cancer. Lung Cancer. 42:1–8. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vonlanthen S, Heighway J, Kappeler A,
Altermatt HJ, Borner MM and Betticher DC: p21 is associated with
cyclin D1, p16INK4a and pRb expression in resectable non-small cell
lung cancer. Int J Oncol. 16:951–957. 2000.PubMed/NCBI
|
|
6
|
Brooks CL and Gu W: p53 ubiquitination:
Mdm2 and beyond. Mol Cell. 21:307–315. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Alt JR, Bouska A, Fernandez MR, Cerny RL,
Xiao H and Eischen CM: Mdm2 binds to Nbs1 at sites of DNA damage
and regulates double strand break repair. J Biol Chem.
280:18771–18781. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bouska A, Lushnikova T, Plaza S and
Eischen CM: Mdm2 promotes genetic instability and transformation
independent of p53. Mol Cell Biol. 28:4862–4874. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li G, Zhai X, Zhang Z, Chamberlain RM,
Spitz MR and Wei Q: MDM2 gene promoter polymorphisms and risk of
lung cancer: a case-control analysis. Carcinogenesis. 27:2028–2033.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hu Z, Ma H, Lu D, et al: Genetic variants
in the MDM2 promoter and lung cancer risk in a Chinese population.
Int J Cancer. 118:1275–1278. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pine SR, Mechanic LE, Bowman ED, et al:
MDM2 SNP309 and SNP354 are not associated with lung cancer risk.
Cancer Epidemiol Biomarkers Prev. 15:1559–1561. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ma H, Hu Z, Zhai X, et al: Polymorphisms
in the MDM2 promoter and risk of breast cancer: a case-control
analysis in a Chinese population. Cancer Lett. 240:261–267. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Onat OE, Tez M, Ozcelik T and Toruner GA:
MDM2 T309G polymorphism is associated with bladder cancer.
Anticancer Res. 26:3473–3475. 2006.PubMed/NCBI
|
|
14
|
Ohmiya N, Taguchi A, Mabuchi N, et al:
MDM2 promoter polymorphism is associated with both an increased
susceptibility to gastric carcinoma and poor prognosis. J Clin
Oncol. 24:4434–4440. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Alhopuro P, Ylisaukko-Oja SK, Koskinen WJ,
et al: The MDM2 promoter polymorphism SNP309T-->G and the risk
of uterine leiomyosarcoma, colorectal cancer, and squamous cell
carcinoma of the head and neck. J Med Genet. 42:694–698. 2005.
|
|
16
|
Bond GL, Hu W, Bond EE, et al: A single
nucleotide polymorphism in the MDM2 promoter attenuates the p53
tumor suppressor pathway and accelerates tumor formation in humans.
Cell. 119:591–602. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Park SH, Choi JE, Kim EJ, et al: MDM2
309T>G polymorphism and risk of lung cancer in a Korean
population. Lung Cancer. 54:19–24. 2006.
|
|
18
|
Zhang X, Miao X, Guo Y, et al: Genetic
polymorphisms in cell cycle regulatory genes MDM2 and TP53 are
associated with susceptibility to lung cancer. Hum Mutat.
27:110–117. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chua HW, Ng D, Choo S, et al: Effect of
MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and
survival among non-smoking Chinese women in Singapore. BMC Cancer.
10:882010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lind H, Zienolddiny S, Ekstrom PO, Skaug V
and Haugen A: Association of a functional polymorphism in the
promoter of the MDM2 gene with risk of nonsmall cell lung cancer.
Int J Cancer. 119:718–721. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu G, Wheatley-Price P, Zhou W, et al:
Genetic polymorphisms of MDM2, cumulative cigarette smoking and
nonsmall cell lung cancer risk. Int J Cancer. 122:915–918. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mittelstrass K, Sauter W, Rosenberger A,
et al: Early onset lung cancer, cigarette smoking and the SNP309 of
the murine double minute-2 (MDM2) gene. BMC Cancer. 8:1132008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bai J, Dai J, Yu H, Shen H and Chen F:
Cigarette smoking, MDM2 SNP309, gene–environment interactions, and
lung cancer risk: a meta-analysis. J Toxicol Environ Health A.
72:677–682. 2009.
|
|
24
|
Gui XH, Qiu LX, Zhang HF, et al: MDM2 309
T/G polymorphism is associated with lung cancer risk among Asians.
Eur J Cancer. 45:2023–2026. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wan Y, Wu W, Yin Z, Guan P and Zhou B:
MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an
updated meta-analysis. BMC Cancer. 11:2082011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wo X, Han D, Sun H, et al: MDM2 SNP309
contributes to tumor susceptibility: a meta-analysis. J Genet
Genomics. 38:341–350. 2011.PubMed/NCBI
|
|
27
|
Bagos PG and Nikolopoulos GK: A method for
meta-analysis of case-control genetic association studies using
logistic regression. Stat Appl Genet Mol Biol. 6:Article 17.
2007.PubMed/NCBI
|
|
28
|
Egger M, Davey Smith G, Schneider M and
Minder C: Bias in meta-analysis detected by a simple, graphical
test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Midgette AS, Wong JB, Beshansky JR, Porath
A, Fleming C and Pauker SG: Cost-effectiveness of streptokinase for
acute myocar-dial infarction: A combined meta-analysis and decision
analysis of the effects of infarct location and of likelihood of
infarction. Med Decis Making. 14:108–117. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Higgins JP, Thompson SG, Deeks JJ and
Altman DG: Measuring inconsistency in meta-analyses. BMJ.
327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rose L SM, Cardwell CR, Jouvet P, McAuley
DF and Blackwood B: Automated versus non-automated weaning for
reducing the duration of mechanical ventilation for critically ill
adults and children. Cochrane Database Syst Rev. 7:CD0092352011.
View Article : Google Scholar
|
|
32
|
Higgins JPT and Green S: Cochrane Handbook
for Systematic Reviews of Interventions, Version 5.1.0, updated
March 2011. The Cochrane Collaboration. 2011.Available from
https://www.cochrane-handbook.org.
|
|
33
|
Li H, Ha TC and Tai BC: XRCC1 gene
polymorphisms and breast cancer risk in different populations: a
meta-analysis. Breast. 18:183–191. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Begg CB and Mazumdar M: Operating
characteristics of a rank correlation test for publication bias.
Biometrics. 50:1088–1101. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Heist RS, Zhou W, Chirieac LR, et al: MDM2
polymorphism, survival, and histology in early-stage non-small-cell
lung cancer. J Clin Oncol. 25:2243–2247. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Han JY, Lee GK, Jang DH, Lee SY and Lee
JS: Association of p53 codon 72 polymorphism and MDM2 SNP309 with
clinical outcome of advanced nonsmall cell lung cancer. Cancer.
113:799–807. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chien WP, Wong RH, Cheng YW, Chen CY and
Lee H: Associations of MDM2 SNP309, transcriptional activity, mRNA
expression, and survival in stage I non-small-cell lung cancer
patients with wild-type p53 tumors. Ann Surg Oncol. 17:1194–1202.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dong J, Ren B, Hu Z, et al: MDM2 SNP309
contributes to non-small cell lung cancer survival in Chinese. Mol
Carcinog. 50:433–438. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jun HJ, Park SH, Lee WK, et al: Combined
effects of p73 and MDM2 polymorphisms on the risk of lung cancer.
Mol Carcinog. 46:100–105. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wan JT, et al: Meta-analysis of
association between SNP309 in MDM2 promoter and lung cancer
susceptibility. Chin J Cancer Prev Treat. 5:655–658. 2008.(In
Chinese).
|
|
41
|
Higgins JP: Commentary: Heterogeneity in
meta-analysis should be expected and appropriately quantified. Int
J Epidemiol. 37:1158–1160. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Groenwold RH, Rovers MM, Lubsen J and van
der Heijden GJ: Subgroup effects despite homogeneous heterogeneity
test results. BMC Med Res Methodol. 10:432010. View Article : Google Scholar : PubMed/NCBI
|
